FDA Has Started 1-Day Unannounced Inspections — And Your Site Could Be Next

This is not a proposal. It is not a pilot that is still being evaluated. It is already happening.

In a May 6, 2026 press announcement, FDA confirmed it has been conducting shorter, focused one-day inspectional assessments since April 2026. As of the announcement, approximately 46 assessments had already been completed. Facilities are being selected right now using risk-based criteria — and most Quality teams have no idea this program exists.

I spent 14 years as an FDA Investigator. When I read the language FDA used to describe this program, I want to make sure every regulated facility understands what it actually says.

What FDA Actually Said

FDA framed the 1-day assessment program as an efficiency measure. Read past that framing and focus on this specific language from the announcement:

Data gathered through these assessments — such as recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations — can be used to better target future oversight activities.

Discrepancies between registered and actual operations. FDA is telling you directly that one purpose of a 1-day assessment is to identify facilities operating outside their registration scope. If your site has added processes, product lines, or contract manufacturing arrangements since your last inspection — and your registration has not been updated to reflect that — you are a target.

The program covers multiple FDA inspectorates. Human and animal foods. Biologics. Medical products. Clinical research programs. This is not a drug-only initiative. If you are a regulated facility of any type, you are in scope.

Why the 1-Day Format Is More Dangerous Than a Standard Inspection

Traditional inspection preparation gives you a runway. You brief your subject matter experts. You stage your document room. You rehearse your escort team. A 1-day assessment collapses that runway to zero.

In many cases your team will not know the visit is happening until an Investigator is already in the lobby. There is no time to locate records, no time to brief anyone, no time to find the right person to answer a question. What your team does in the first 30 minutes is all there is.

And here is the detail that should concern every Quality Director reading this: assessments have extended beyond one day when significant observations were identified. A 1-day visit that becomes a multi-day investigation is the worst possible outcome. It means your facility gave the Investigator a reason to stay.

Who Gets Selected

FDA is using risk-based selection criteria. Prior inspection outcomes are a primary factor. A prior 483 observation, a Warning Letter history, or an adverse event pattern elevates your facility’s risk score. Product type and operational characteristics also factor in.

If your last inspection ended with observations that were closed on paper but not fully remediated in practice, your risk score is elevated. If your registration does not accurately reflect what your facility currently does, your risk score is elevated. If your quality system cannot produce core documentation within minutes, your risk posture will be visible the moment an Investigator walks in.

You have time right now to address all of this. Most facilities are not using it.

What Comes After a 1-Day Assessment

A 1-day assessment is not a courtesy visit. Investigators conducting these assessments have the same authority available to them as a standard inspection. Observations made during a 1-day assessment can trigger a full follow-up inspection. Risk scores generated from these visits can influence your facility’s regulatory standing for years.

The facilities that come out of these assessments cleanly are not necessarily the most technically compliant. They are the ones in a continuous state of inspection readiness — where the answer to any document request is measured in minutes, not hours, and where every person on the floor knows exactly what to do when a stranger walks in with credentials.

The Full Playbook Is in The Investigator’s Lens

How to audit your registration against actual operations. How to run a real unannounced mock assessment. What FDA Investigators focus on first in a compressed one-day visit. How to eliminate the specific conditions that trigger scope escalation.

That intelligence is in the paid edition of The Investigator’s Lens — written by former FDA Investigators who have conducted exactly the type of assessment FDA is now deploying at scale.

Read the full article here: https://devaughnedwards.substack.com/p/regulatory-alert-fdas-new-supplemental?r=7sflcx

DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.

Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831